ERBB2 and glioblastoma: Clinical trials investigating CAR T cell therapy for glioblastoma are targeting five antigens: EphA2,430 EGFRvIII,431,432 HER2,433 interleukin 13 receptorα2 (IL13Rα2),434,435 and GD2436,437 (Table 3).